CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D001171: Arthritis, Juvenile NIH

(Synonyms: Arthritis, Ju, Arthritis, Juvenile)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug497 CT-Scan Wiki 0.71

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D001168 Arthritis NIH 0.29

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0001369 Arthritis HPO 0.29

There is one clinical trial.

Clinical Trials


1 Drug Management of Juvenile Idiopathic Arthritis in Covid-19 Context

The current situation of Sars-Cov-2 pandemic generates fears in the general population. Among patients receiving long-term immunomodulatory drugs, especially in the context of auto-immune diseases, there may be legitimates interrogations about the appropriateness of continuing treatment, without modification, in the current context. Juvenile Idiopathic Arthritis is concerns by these fears (the patient and their parents). Patients are treated by several classes of immunomodulatory drugs, including non-steroidal anti-inflammatory drugs, corticosteroids and disease modifying anti-rheumatic drugs. The present study will characterize this issue by defining the proportion of patients whose usual treatment of Juvenile Idiopathic Arthritis has been modified in relation to the actual sanitary crisis, and also to return to school.

NCT04407923 Juvenile Idiopathic Arthritis COVID 19 Treatment
MeSH:Arthritis Arthritis, Juvenile
HPO:Arthritis Polyarticular arthritis

Primary Outcomes

Description: Reduction or discontinuation of treatment with sDMARD, bDMARD or tsDMARD

Measure: Reduction or discontinuation of the DMARD therapy in relation to the Covid-19 sanitary crisis

Time: 1 Day


HPO Nodes